Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hibi is a prominent brand of antiseptic and disinfectant products, with **chlorhexidine gluconate** as the primary active ingredient. Originally developed by Imperial Chemical Industries (ICI) in the 1950s and currently marketed by Mölnlycke Health Care, the Hibi range (including Hibiscrub and Hibiclens) is a cornerstone of infection control in clinical settings. It is primarily used for pre-operative skin preparation, surgical hand scrubbing, and general skin disinfection. Chlorhexidine is a bisbiguanide antiseptic that exerts its antimicrobial effect by binding to the negatively charged surfaces of bacterial cell walls and membranes. This binding causes a loss of membrane integrity, leading to the leakage of intracellular contents and, at higher concentrations, the coagulation of cytoplasmic proteins, resulting in cell death. It is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, as well as certain fungi and enveloped viruses, and is valued for its persistent antimicrobial activity on the skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hibi.